Dr. Vladimir Malinin is an Executive Director of Research at Insmed Incorporated based in Bridgewater, New Jersey, United States. Vladimir received his master’s degree in Biophysics from the Department of Medical Biology, Russian State Medical University in 1988. He earned his Ph.D. degree in Biophysics in 1994 from the Institute for Physical Chemical Medicine, Moscow, Russia. In 1998, Vladimir joined Professor Barry Lentz’s Lab at the UNC - Chapel Hill, NC as a postdoctoral associate where he studied lipid bilayer fusion processes. Vlad began his career in the biotech-pharmaceutical industry in 2000 as a Scientist at The Liposome Company, Princeton, NJ. In 2003 he joined Insmed Incorporated (formerly Transave Inc.). At Insmed he has been instrumental in research and development of the company’s pipeline and leads the Discovery and Formulation efforts. Vladimir was the key inventor of a number of Insmed patents including Insmed’s first commercial product ARIKAYCE®, approved in 2018 in the US for treatment of non-tuberculous mycobacteria lung infections, and INS1009, an inhaled prostanoid prodrug in clinical development for treatment of pulmonary arterial hypertension.